KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Jazz Pharmaceuticals (JAZZ) Gross Margin: 2009-2025

Historic Gross Margin for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to 88.56%.

  • Jazz Pharmaceuticals' Gross Margin fell 87.00% to 88.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.63%, marking a year-over-year decrease of 75.00%. This contributed to the annual value of 89.05% for FY2024, which is 41.00% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Gross Margin of 88.56% as of Q3 2025, which was up 0.24% from 88.35% recorded in Q2 2025.
  • Jazz Pharmaceuticals' Gross Margin's 5-year high stood at 93.39% during Q1 2021, with a 5-year trough of 82.67% in Q3 2021.
  • For the 3-year period, Jazz Pharmaceuticals' Gross Margin averaged around 88.75%, with its median value being 89.33% (2023).
  • In the last 5 years, Jazz Pharmaceuticals' Gross Margin tumbled by 1,087bps in 2021 and then skyrocketed by 662bps in 2023.
  • Jazz Pharmaceuticals' Gross Margin (Quarterly) stood at 84.82% in 2021, then plummeted by 203bps to 82.78% in 2022, then surged by 662bps to 89.40% in 2023, then slumped by 123bps to 88.17% in 2024, then plummeted by 87bps to 88.56% in 2025.
  • Its last three reported values are 88.56% in Q3 2025, 88.35% for Q2 2025, and 88.17% during Q4 2024.